Accuitis to trial ACU-D1 for Rosacea

Written by on March 6, 2017 in clinical trials, New Rosacea Treatments with 2 Comments


A drug that is said to inhibit nuclear factor kappa beta (NFkB), is to be trialed as a rosacea treatment. The new treatment, code named ACU-D1 will be tested as a treatment primarily for the papules and pustules of rosacea.

Clinical Trial NCT03064438

Efficacy of Accu-D1 in the Treatment of Acne Rosacea

The study evaluates the safety, efficacy and tolerability of ACCU-D1 when applied twice daily for 12 weeks in adult patients with moderate to severe acne rosacea. Two thirds of participants will receive ACCU-D1 while one third will receive vehicle control.

Primary Outcome Measures: Total Inflammatory Lesion Count [ Time Frame: 12 weeks ] Efficacy as measure by total inflammatory lesion counts

What is ACU-D1?

According to the Accuituis web site;


Our lead discovery compound has activity against the 26S proteasome, one of the beneficial effects of blocking the proteasome is to inhibit the transcription factor nuclear factor kappa beta (NFkB), which is a potent mediator of inflammation.

NFkB has already been shown to be a major, if not the major mediator of skin diseases including Rosacea, Psoriasis, and Acne. In these conditions, inflammation, excess blood vessels, and the enzymes that digest elastic fibers in the skin, are mediated by NFkB. Currently, there are no topical therapies to address proteasomes.

Our compound also has the advantage of extensive toxicology testing in multiple animal species, as well as a safe record of human exposure for over 30 years. ACU-D1 has been formulated into a stable and cosmetically acceptable product which delivers therapeutically relavent concentrations of active to the dermis.

The company further claims that “Our lead product is a transformational first in class treatment for Rosacea.” Time will tell.

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

2 Reader Comments

  1. Nicola Ingrosso says:

    I would appreciate any info on ocular rosacea….I have my skin under control but my I am at my wits end with my eyes..
    Please help.

    • Ita Dolha says:

      Been battling the same since Oct 2015. Currently using Cliradex wipes. Have run the gamut, probably much like yourself.
      Symptoms wax and wane. Unable to tolerate doxy d/t allergic rxn, but was better on doxy 50 mgs than not.
      Better with anti-inflammatory AIP diet/low carb.

      Had a Cliradex Cream treatment yesterday at an optomotrist’s office where they paint Cliradex cream from your eyebrows, over the lids and down the lashes. The cream was left on for 12 mins with the eyes closed as it absorbed. A second application was applied for another 12 mins. There was marked reduction in eyelid swelling post RX. Two more RXes at 21 and 42 days to follow the life cycle of the Demodex mite will be done. The treatment caused some tingling on the lids and minor temporary eye redness, but my eyes are super sensitive. I will do anything to lose this blight on my eyes! The idea behind the treatment is to kill the Demodex when they live inside the MBGs. The active ingredient in TTO is 4-Terapin which is in the Cliradex wipe and cream. I had initially phoned the clinic to inquire about Blephex treatment and that is how I heard about this novel treatment. Good luck!

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.